Oncotarget

Research Papers:

DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling

Shiu-Wen Huang, Jin-Cherng Lien, Sheng-Chu Kuo and Tur-Fu Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:63124-63137. https://doi.org/10.18632/oncotarget.11152

Metrics: PDF 1625 views  |   HTML 1853 views  |   ?  


Abstract

Shiu-Wen Huang1, Jin-Cherng Lien2, Sheng-Chu Kuo2, Tur-Fu Huang1

1Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan

2Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung, Taiwan

Correspondence to:

Tur-Fu Huang, email: [email protected]

Keywords: angiogenesis, anthraquinone, endothelial cells, VEGFR

Received: October 13, 2015     Accepted: July 26, 2016     Published: August 09, 2016

ABSTRACT

As angiogenesis is required for tumor growth and metastasis, suppressing angiogenesis is a promising strategy in limiting tumor progression. Vascular endothelial growth factor (VEGF)-A, a critical pro-angiogenic factor, has thus become an attractive target for therapeutic interventions in cancer. In this study, we explored the underlying mechanisms of a novel anthraquinone derivative DDA in suppressing angiogenesis. DDA inhibited VEGF-A-induced proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs). DDA also reduced VEGF-A-induced microvessel sprouting from aortic rings ex vivo and suppressed neovascularization in vivo. VEGF-A-induced VEGFR1, VEGFR2, FAK, Akt, ERK1/2 or STAT3 phosphorylation was reduced in the presence of DDA. In addition, NRP-1 siRNA reduced VEGF-A’s enhancing effects in VEGFR2, FAK and Akt phosphorylation and cell proliferation in HUVECs. DDA disrupted VEGF-A-induced complex formation between NRP-1 and VEGFR2. Furthermore, systemic administration of DDA was shown to suppress tumor angiogenesis and growth in in vivo mouse xenograft models. Taken together, we demonstrated in this study that DDA exhibits anti-angiogenic properties through suppressing VEGF-A signaling. These observations also suggest that DDA might be a potential drug candidate for developing anti-angiogenic agent in the field of cancer and angiogenesis-related diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11152